• No results found

Original Article Synergistic effects of curcumin and bortezomib on multiple myeloma cells

N/A
N/A
Info
Download
Protected

Academic year: 2020

Share "Original Article Synergistic effects of curcumin and bortezomib on multiple myeloma cells"

Copied!
7
0
0

Loading.... (view fulltext now)

Download now ( 7 Page )

Full text

Figure

Figure 1. Effects of curcumin and bortezomib on MM1.R cell proliferation. Half of the MM1.R cells were treated with curcumin alone at 0, 10, 20, and 40 mg/mL, respectively, for 24 h, while the other half were treated with bortezomib (0.01 mmol/L) combined
Figure 2. Effects of curcumin and bortezomib on apoptosis of MM1.R cells. Half of the MM1.R cells were treated with curcumin alone at 0, 10, 20, and 40 mg/mL, respectively, for 24 h, while the other half were treated with bortezomib (0.01 mmol/L) combined
Figure 3. Effects of curcumin and bortezomib on expression of apoptosis-related proteins in MM1.R cells

References

Download now ( PDF - 7 Page - 1.02 MB )

Related documents

Original Article Curcumin protects mesenchymal stem cells against oxidative stress-induced apoptosis via Akt/mTOR/p70S6K pathway

pathway and cell apoptosis in BM-MSCs, and the Akt inhibitor perifosine can largely abolish the protective effects of curcumin, which sug- gests that curcumin protects BM-MSCs

Original Article Knockdown of Gli1 by small-interfering RNA enhances the effects of BCNU on the proliferation and apoptosis of glioma U251 cells

In con- clusion, the combined treatment with siRNA- Gli1 and BCNU significantly inhibits the prolif - eration and promotes the apoptosis of glioma U251 cells, possibly by

Original Article Establishment of stable multiple myeloma cell line with overexpressed PDCD5 and its proapoptosis mechanism

The proapoptotic action of PDCD5 gene had the effect of activating casepase-3 and downregulating survivin and Bcl-2, which further promoted the apoptosis of multiple myeloma

Original Article A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide

Although the introduction of lenalidomide combined with dexamethasone (Len/Dex) has improved the outcome of patients with relapsed/refractory multiple myeloma (RRMM), it is a

Original Article Diallyl trisulfide inhibits proliferation and promotes apoptosis of side population cells in multiple myeloma cells

In this study, we found that bortezomib treat- ment significantly reduced the survival rate and colony formation, arrested the cell cycle, and promoted the apoptosis of SP

Original Article Cyp1a1 is involved in drug resistance to bortezomib in CD138 myeloma cells

Mor- eover, Notch inhibiting by DAPT in CD138 - cells resulted in increased sensitivity to bortezomib treatment for 48 h (Figure 2C), indicating that cyp1a1 may be involved in

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation..

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts

In vitro, Aplidin potently inhibited MM cell growth and induced apoptosis, effects that were enhanced by dexamethasone (Dex) and bortezomib (Btz). Aplidin modestly reduced